An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer

This is an open-label, fixed-sequence Phase I clinical trial to evaluate the effect of HS-10504 on the pharmacokinetics of midazolam (CYP3A4 substrate) in patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression during or after treatment with EGFR-TKIs.

NCT Number	NCT07685041
Lead Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions	NSCLC
Enrollment	24 participants
Start Date	2026-06-27
Primary Completion	2026-11-19 (estimated)
Study Completion	2027-07-20 (estimated)
Updated on ClinicalTrials.gov	2026-07-06